

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
P. Do. 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.			Alexandria, Virginia 22313-14 www.uspto.gov	50	
09/522,434	93/09/2000	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO. CONFIRMATION NO.		
		Feng-Nien Ko		CONFIRMATION NO.	
	7590 05/06/2003 HARDSON PC IN ST 		11544-003001	3204	
225 FRANKLIN BOSTON, MA			EXAMI	NER	
			COE, SUSAN D		
			ART UNIT	PAPER NUMBER	
			1654		
			DATE MAILED: 05/06/2003	DATE MAILED: 05/06/2003	

Please find below and/or attached an Office communication concerning this application or proceeding.

		LE COPY
•	Application No.	Appint(s)
Office Action Summary	09/522,434	KO ET AL.
and the second s	Examiner	Art Unit
The MAILING DATE of this communication	Susan Coe	1654
The MAILING DATE of this communication Period for Reply	appears on the cover sheet w	ith the correspondence address
A SHORTENED STATUTORY PERIOD FOR REI THE MAILING DATE OF THIS COMMUNICATIOI - Extensions of time may be available under the provisions of 37 CFR after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a - If NO period for reply is specified above, the maximum statutory peri - Failure to reply within the set or extended period for reply will, by sta - Any reply received by the Office later than three months after the ma earned patent term adjustment. See 37 CFR 1.704(b). Status	N. 8.1.136(a). In no event, however, may a reply within the statutory minimum of thir iod will apply and will expire SIX (6) MON	reply be timely filed ty (30) days will be considered timely. NTHS from the mailing date of this communication.
1) Responsive to communication(s) filed on $\underline{0}$	1 <u>4 March 2003</u> .	
2a) ☐ This action is FINAL . 2b) ☑	This action is non-final.	
3) Since this application is in condition for allo	wance except for formal ma	tters, prosecution as to the merits is
Disposition of Claims	er <i>Ex рапе Quayle</i> , 1935 С.I	D. 11, 453 O.G. 213.
4)⊠ Claim(s) <u>1,3-5,7-9 and 11-37</u> is/are pending	in the application.	
4a) Of the above claim(s) <u>3-5,7-9 and 12-37</u>	is/are withdrawn from consid	deration.
5) Claim(s) is/are allowed.		
6)⊠ Claim(s) <u>1 and 11</u> is/are rejected.		
7) Claim(s) is/are objected to.		
8) Claim(s) are subject to restriction and	l/or election requirement.	
Application Papers		
9) The specification is objected to by the Examir		
10) The drawing(s) filed on is/are: a) acc		
Applicant may not request that any objection to	the drawing(s) be held in abeya	nce. See 37 CFR 1.85(a).
11) The proposed drawing correction filed on	is: a)□ approved b)□ di	sapproved by the Examiner.
If approved, corrected drawings are required in r		
12) The oath or declaration is objected to by the E	xaminer.	
riority under 35 U.S.C. §§ 119 and 120		
13) Acknowledgment is made of a claim for foreign	gn priority under 35 U.S.C. §	119(a)-(d) or (f).
a) ☐ All b) ☐ Some * c) ☐ None of:		
1. Certified copies of the priority documer		
2. Certified copies of the priority documer	nts have been received in Ap	plication No
 Copies of the certified copies of the pricapplication from the International B See the attached detailed Office action for a lis 	Ureau (PCT Rula 17 2/a)\	
14) Acknowledgment is made of a claim for domes	tic priority under 35 U.S.C. 8	119(e) (to a provisional application)
 a) ☐ The translation of the foreign language pr 	ovisional application has bee	en received
15) Acknowledgment is made of a claim for domes	tic priority under 35 U.S.C. §	§ 120 and/or 121.
tachment(s)	•	
 ✓ Notice of References Cited (PTO-892) ✓ Notice of Draftsperson's Patent Drawing Review (PTO-948) ✓ Information Disclosure Statement(s) (PTO-1449) Paper No(s) 	5) Notice of Ind	ummary (PTO-413) Paper No(s). <u>21</u> . formal Patent Application (PTO-152)

U.S. Pa

Application/Control Number: 09/522,434 Page 2

Art Unit: 1654

DETAILED ACTION

The text of those sections of Title 35, U.S. Code, not included in this action can be found in a prior Office action.

Continued Examination Under 37 CFR 1.114

- 1. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on March 4, 2003 has been entered.
- 2. Claims 23-37 have been added. Claims 1, 3-5, 7-9, and 11-37 are currently pending.

Election/Restrictions

- 3. As stated on page 2 of the Office action of August 27, 2002, in Paper No. 7, dated March 14, 2001, applicants elected without traverse of Group, claims 1-11, and the extraction procedure of claim 3 (extraction with a solvent having a polarity higher that 0.88). In response to the Office action of August 28, 2001, applicant effectively cancelled the elected species with the amendments to claim 1. Thus, in accordance with MPEP section 803.02, the new species selected for examination is the extraction procedure claimed in claim 1.
- 4. Claims 3-5, 7-9, and 12-37 are withdrawn from consideration as being drawn to non-elected invention and species.
- 5. Claims 1 and 11 are examined on the merits.

,

Application/Control Number: 09/522,434

Art Unit: 1654

Claim Objections

Claim 1 is objected to because of the following informalities: in line 6 "consisting" should be "consists" and in line 7 "trough" should be "through." Appropriate correction is required.

Claim Rejections - 35 USC § 102

6. Claims 1 and 11 are rejected under 35 U.S.C. 102(b) as being anticipated by US Pat. No. 4,317,816.

Applicant's claims are directed towards a composition containing an American ginseng extract which consists essentially of components with a molecular weight greater than 1,000.

US '816 teaches a saponin extracted from American ginseng. The extract is made by extracting the plant in various solvents, filtering, and drying (see claim 2; column 41-49; and column 5, lines 30-55). The saponin is at least one ginsenoside from a variety of disclosed ginsenosides (see column 3, lines 4-6). Of the ginsenosides disclosed, ginsenoside Rb1, Rb2, Rc, and Rb3 all have a molecular weight of greater than 1000 (see column 4, lines 1-14). Therefore, the reference teaches a composition that contains an extract from American ginseng that can only have components with a molecular weight greater than 1000.

The reference does not specifically teach that an ultrafiltration membrane with a molecular weight cut-off of 1,000 is used; however, the ginsenosides extracted have a molecular weight greater than 1. Therefore, the composition extracted by the reference appears to be the same as the claimed composition. The reference does not teach that the ginsenosides treat ulcers;

Application/Control Number: 09/522,434

Art Unit: 1654

however, due to the fact that the composition of US '816 is the same as the claimed composition, the composition of US '816 would inherently have the same effects on the human body as the claimed composition.

7. Claims 1 and 11 are rejected under 35 U.S.C. 102(b) as being anticipated by Derwent English abstract of JP 04316507 A for the reasons set forth on page 3 of the Office action of August 27, 2002.

All of applicant's arguments regarding this ground of rejection have been fully considered but are not persuasive. Applicant argues that the reference contains compounds that have a molecular between 1,000 and 10,000. Applicant bases this assertion on Yoshikawa et al. which teaches an American ginseng extract that has molecular weights between 1,000 and 10,000. However, Yoshikawa does not negate the teaching of the reference. The reference specifically states that American ginseng extract is ultrafiltered to "give a component having a molecular weight of 10,000 daltons or over (third paragraph)." Thus, the reference teaches an American ginseng extract that contains a component over 10,000 and does not contain any components under this weight. These components would not be in the composition because they would have been removed during the ultrafiltration step. Therefore, the teaching of Yoshikawa does not seem relevant to the rejection based on the clear teaching by the reference of an extract that does not contain components of a molecular weight of less than 10,000.

8. Claims 1 and 11 are rejected under 35 U.S.C. 102(b) as being anticipated by English abstract of JP 61109732 A for the reasons set forth on pages 3 and 4 of the Office action of August 27, 2002.

All of applicant's arguments regarding this ground of rejection have been fully considered but are not persuasive. Applicant traverses this rejection for the same reasons stated for the rejection based on JP '507. However, this reference is considered to anticipate the claims because the reference teaches isolating a specific polysaccharide that has a molecular weight of 100,000. Since this is an isolated component, other components with different molecular weights have been excluded. Therefore, the reference is considered to teach a composition extracted from American ginseng that does not contain components of a molecular weight of less that 1,000.

9. No claims are allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Susan Coe whose telephone number is (703) 306-5823. The examiner can normally be reached on Monday to Thursday from 8:00 to 5:30 and on alternating Fridays.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Brenda Brumback, can be reached on (703) 306-3220. The fax phone number for the organization where this application or proceeding is assigned is (703) 872-9306.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.

Susan Coe, Examiner May 1, 2003

LEON B. VANKFORD, JR. PRIMARY EXAMINER